Arecor Therapeutics PLC ARECOR ANNOUNCES ORAL PRESENTATION AT ATTD 2022
12 April 2022 - 4:01PM
RNS Non-Regulatory
TIDMAREC
Arecor Therapeutics PLC
12 April 2022
Arecor Therapeutics plc
("Arecor" or the "Group")
ARECOR ANNOUNCES ORAL PRESENTATION AT ATTD 2022 OF
PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID
ACTING INSULIN FOR DIABETES
Cambridge, UK , 12 April 2022: Arecor Therapeutics plc (AIM:
AREC), a globally focused biopharmaceutical company advancing
today's therapies to enable healthier lives, today announces that
its abstract titled " AT278 (U500) - PK/PD and safety of
rapid-acting concentrated insulin aspart ", has been selected for
oral presentation at the upcoming 15(th) International Conference
on Advanced Technologies and Treatments For Diabetes (ATTD )
meeting which will be held from 27-30 April 2022 in Barcelona.
The presentation will take place at 17:20 on Thursday 28 April
during the Oral Presentations Session 2 in Hall 118 of the
Conference Centre.
Oral Presentation: AT278 (U500) - PK/PD and safety of
rapid-acting concentrated insulin aspart
Presenting Author: Dr Eva Svehlikova
Session: Oral Presentations Session 2
Date and Time: Thursday, 28 April 2022, at 17:20 Central European Time
AT278 is an ultra-concentrated (500U/mL) novel formulation of
insulin that has been designed to significantly accelerate insulin
absorption post injection to enable more effective and convenient
management of blood glucose levels in people with high daily
insulin requirements.
In addition, a poster titled 'Adjusting insulin therapy to
faster insulin analogs leads to improved glucose control: An
in-silico analysis' will be presented at ATTD by Dr Jenny Diaz from
the University of Virginia. The in-silico analysis suggests that
the faster PK/PD profile of Arecor's AT247, an investigational
ultra-rapid acting (100U/mL) insulin formulation, has the potential
to significantly improve glucose control in closed loop
systems.
Sarah Howell, Chief Executive Officer at Arecor, said: "We are
very excited to be able to share these ground-breaking data for
AT278 and AT247 at the ATTD conference. AT278 has the potential to
be the first and perhaps only concentrated (500U/mL) rapid acting
insulin available to patients, having clearly demonstrated faster
insulin absorption with an accelerated pharmacokinetic (PK) and
pharmacodynamic (PD) profile compared to gold-standard insulin
NovoRapid(R) despite a 5-fold increase in concentration, in this
first Phase I clinical study. In addition, in partnership with the
University of Virginia, we are excited to be able to share results
from their in-silico analysis demonstrating the potential for AT247
to enable a fully closed loop artificial pancreas, which would be a
life-changing treatment option for people living with Type 1
diabetes."
About the ATTD
The International Conference on Advanced Technologies and
Treatments of Diabetes (ATTD) was established in 2008 and has held
annual meetings since then. The purpose of the ATTD meeting is to
highlight innovative technologies in diabetes treatment. It brings
together developers of new technologies with the diabetes
professionals and caretakers as well as acquainting clinicians with
techniques for new treatments.
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited (NOMAD
and Broker)
Freddy Crossley, Emma Earl (Corporate Tel: +44 (0) 20 7886 2500
Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications
Chris Gardner, David Daley, Angela Tel: +44 (0) 20 3709 5700
Gray Email: arecor@consilium-comms.com
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical
group transforming patient care by bringing innovative medicines to
market through the enhancement of existing therapeutic products. By
applying our innovative proprietary formulation technology
platform, Arestat(TM), we are developing an internal portfolio of
proprietary products in diabetes and other indications, as well as
working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The
Arestat(TM) platform is supported by an extensive patent
portfolio.
For further details please see our website, www.arecor.com
About AT278
AT278 is Arecor's ultra-concentrated, ultra-rapid acting insulin
designed to accelerate the absorption of insulin post injection, to
enable more effective management of blood glucose levels to the
increasing number of people with diabetes with high daily insulin
requirements (>200 units/day), whilst maintaining the
convenience and compliance benefits of being able to deliver these
high insulin doses in a lower injection volume via a single
injection. A truly rapid acting concentrated insulin is a critical
step towards the advancement and miniaturisation of the next
generation of insulin delivery devices.
About AT247
AT247 is an ultra-rapid insulin that aims to accelerate insulin
absorption, post injection, to enable more effective management of
blood glucose levels for people living with diabetes, particularly
around difficult to manage mealtimes. Early clinical evidence
suggests that AT247 may facilitate a fully closed loop artificial
pancreas, a potentially life changing treatment option for people
living with diabetes, and a US Phase I clinical trial is currently
underway investigating the potential of the product when delivered
by continuous subcutaneous infusion via insulin pump.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAKZGMDLMVGZZM
(END) Dow Jones Newswires
April 12, 2022 02:01 ET (06:01 GMT)
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Apr 2023 to Apr 2024